Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines
NCT03999554
Completed
This is a Phase I double-blind, randomized, placebo-controlled study in 250 healthy adults, 18-49 years of age, inclusive, who are in good health and meet all eligibility criteria. The purpose of this dose escalation clinical study is to assess the safety, tolerability/reactogenicity, and immunogenicity of H3N2 M2SR investigational vaccines for prevention of influenza, when delivered at higher dosages or in two doses . Eligible subjects will be screened and randomized to receive two administrati... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
12/10/2021
Locations: RCA, Hollywood, Florida +3 locations
Conditions: Influenza A
Register for Updates
A Safety and Immunogenicity Trial of IHV01
NCT02756208
Completed
This study is designed to evaluate the safety of the FLSC vaccine and will be a randomized, placebo-controlled, modified double-blinded dose escalation study in 60 healthy adult volunteers (Human Immunodeficiency Virus-1 uninfected).
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
11/15/2021
Locations: University of Maryland, Institute of Human Virology, Baltimore, Maryland
Conditions: HIV Infection
Register for Updates
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
NCT00427895
Completed
This study will assess the safety, tolerability and immune response of 13-valent pneumococcal conjugate vaccine (13vPnC) compared with 23-valent Pneumococcal Polysaccharide Vaccine (23vPS). Although the study started with only 1 population, amendments to the original protocol will now reflect three participant populations. Three age cohorts will be enrolled. The first cohort (age 60-64) will be blinded. Cohort 2 (age 50-59) and cohort 3 (age 18-49) are open label. Subjects in cohorts 1 and 2 wil... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
11/11/2021
Locations: Accelovance, Huntsville, Alabama +25 locations
Conditions: Pneumococcal Infections
Register for Updates
Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients
NCT00080106
Completed
HIV vaccines may help the immune systems of HIV infected patients better control the virus. The goal of this study is to determine whether patients on anti-HIV medications can stop taking those medications if they receive an HIV vaccine. While taking anti-HIV medications, participants will receive either an HIV vaccine or a placebo. Participants will then stop taking their anti-HIV medications and the study will compare the viral loads of participants who received the vaccine with the viral load... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
11/04/2021
Locations: UCLA CARE Center CRS, Los Angeles, California +27 locations
Conditions: HIV Infections
Register for Updates
Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women
NCT01461096
Completed
Men who have sex with men (MSM) have an increased risk of developing anal human papillomavirus (HPV) infections, which can be a risk factor for anal cancer. HIV-infected women are also at risk of anal cancer. This study will evaluate the effectiveness of the Food and Drug Administration (FDA)-approved quadrivalent HPV vaccine, Gardasil, at preventing anal HPV infection in HIV-infected MSM and HIV-infected women.
Gender:
ALL
Ages:
27 years and above
Trial Updated:
10/29/2021
Locations: UCLA CARE Center CRS, Los Angeles, California +23 locations
Conditions: HIV Infections
Register for Updates
Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs
NCT00013871
Completed
The purpose of this study is to determine if 2 doses of Pneumococcal Conjugate Vaccine (PCV) followed by 1 dose of Pneumococcal Polysaccharide Vaccine (PPV) in HIV-infected children on anti-HIV therapy is helpful and safe in fighting pneumococcal infections in this group of children. This study will also look at the protection provided by childhood vaccination against measles, pertussis, and hepatitis B virus. Pneumococcal infections are the most common AIDS-related infection in HIV-infected ch... Read More
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
10/28/2021
Locations: UAB, Dept. of Ped., Div. of Infectious Diseases, Birmingham, Alabama +39 locations
Conditions: HIV Infections, Hepatitis B, Measles, Pneumococcal Infections, Pertussis
Register for Updates
Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents
NCT00091702
Completed
The purpose of this study is to compare two flu vaccines to determine their safety and ability to stimulate an immune response in HIV infected children and adolescents. This study will also determine how often and how long people who receive a vaccine are able to spread flu vaccine virus to other people.
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
10/28/2021
Locations: UAB, Dept. of Ped., Div. of Infectious Diseases, Birmingham, Alabama +60 locations
Conditions: HIV Infections, Influenza
Register for Updates
Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs
NCT00257127
Completed
The purpose of this study is to determine immune system function following vaccination in HIV-infected children currently taking anti-HIV drugs. To test the effectiveness of prior vaccination, patients in this study will receive booster shots of one of two pneumococcal vaccines, a hepatitis B vaccine, and a measles vaccine.
Gender:
ALL
Ages:
Between 6 years and 23 years
Trial Updated:
10/28/2021
Locations: UAB, Dept. of Ped., Div. of Infectious Diseases, Birmingham, Alabama +25 locations
Conditions: HIV Infections
Register for Updates
Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors
NCT02747407
Completed
This research trial studies qualitative, qualitative, and functional studies over the first year in measuring immune system response in patients with brain tumors. Measuring the number of immune cells, whether these immune cells work correctly, and response to 2 vaccines at several times during the first year of treatment may help find out how active the immune system responds to fight infection and cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2021
Locations: Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina
Conditions: Astrocytoma, Glioma, Oligodendroglioma
Register for Updates
Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults
NCT01260727
Completed
The purpose of this study is to evaluate the safety of and immune response to an HIV vaccine, administered using two different devices, followed by a vaccine boost, in healthy, HIV-uninfected adults.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
10/28/2021
Locations: Rockville Vaccine Assessment Clinic (RVAC), Rockville, Maryland +3 locations
Conditions: HIV Infections
Register for Updates
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)
NCT00000767
Completed
To evaluate, in healthy HIV-1 seronegative vaccinia-immune and vaccinia-naive volunteers, the safety and immunogenicity of an HIV-1 candidate vaccine (TBC-3B) consisting of a live recombinant vaccinia virus expressing the env, gag, and pol genes of HIV-1 IIIB strain. To evaluate the potential of boosting with one of a variety of HIV-1 recombinant subunit, peptide, or pseudovirion vaccines, if available, to augment the immune responses of the vaccinees. Antigenic drift, defined as the genetic va... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
10/27/2021
Locations: St. Louis Univ. School of Medicine AVEG, Saint Louis, Missouri +4 locations
Conditions: HIV Infections
Register for Updates
A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen
NCT00000782
Completed
To determine the frequency of delayed-type hypersensitivity (DTH) reactions in HIV-positive patients to two doses of two envelope glycoprotein antigens prepared differently. To determine whether patients who have previously demonstrated a DTH response to intradermal MGStage HIV-1 gp160 IIIB baculovirus (MicroGeneSys) have a reproducible response to a repeat injection of gp160 and whether there is cross-reactivity to intradermal HIV-1 rgp160 IIIB vero cell expressed (Immuno-AG). PER 4/5/95 AMEND... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/27/2021
Locations: Stanford CRS, Palo Alto, California +3 locations
Conditions: HIV Infections
Register for Updates